Literature DB >> 19716405

Down syndrome candidate region-1 protein interacts with Tollip and positively modulates interleukin-1 receptor-mediated signaling.

Jae Youn Lee1, Hyun Jung Lee, Eun Jung Lee, Sung Hee Jang, Hyeyoung Kim, Joo-Heon Yoon, Kwang Chul Chung.   

Abstract

BACKGROUND: The Down syndrome candidate region-1 gene (DSCR1, also known as RCAN1) is situated close to the Down Syndrome Critical Region (DSCR), which contains genes responsible for many features of Down syndrome. DSCR1 modulates calcineurin phosphatase activity, though its functional role is incompletely understood.
METHODS: Here we investigated the role of DSCR1-1S isoform in IL-1 receptor (IL-1R)-mediated signaling by analyzing interaction between DSCR1-1S and the IL-1R pathway components Tollip, IRAK-1, and TRAF6.
RESULTS: Co-immunoprecipitation analyses of HEK293 cells revealed that DSCR1-1S interacted with Tollip, an IRAK-1 inhibitor, leading to the dissociation of IRAK-1 from Tollip. Similarly, both DSCR1-1S and Tollip interacted with TRAF6, with DSCR1 reducing interaction between Tollip and TRAF6. DSCR1-1S also stimulated IL-1R-mediated signaling pathways, TAK1 activation, NF-kappaB transactivation, and IL-8 production, all downstream consequences of IL-1R activation. GENERAL SIGNIFICANCE: Together, these results suggest that DSCR1-1S isoform positively modulates IL-1R-mediated signaling pathways by regulating Tollip/IRAK-1/TRAF6 complex formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716405     DOI: 10.1016/j.bbagen.2009.08.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Regulator of Calcineurin 1 Isoform 4 (RCAN1.4) Is Overexpressed in the Glomeruli of Diabetic Mice.

Authors:  Chorong Jang; Ji Hee Lim; Cheol Whee Park; Young-Jin Cho
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

2.  Down Syndrome Candidate Region 1 Isoform 1L regulated tumor growth by targeting both angiogenesis and tumor cells.

Authors:  Chen Chen; Pengfei Cui; Kevin Zhao; Gengming Niu; Shiqiang Hou; Dezheng Zhao; Huiyan Zeng
Journal:  Microvasc Res       Date:  2021-12-24       Impact factor: 3.750

3.  Histone deacetylase 3 promotes RCAN1 stability and nuclear translocation.

Authors:  Kyung Ah Han; Hye Seon Kang; Jee Won Lee; Lang Yoo; Eunju Im; Ahyoung Hong; Yun Ju Lee; Woo Hyun Shin; Kwang Chul Chung
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

4.  Leucine-Rich Repeat Kinase 2 (LRRK2) Stimulates IL-1β-Mediated Inflammatory Signaling through Phosphorylation of RCAN1.

Authors:  Kyung A Han; Lang Yoo; Jee Y Sung; Sun A Chung; Ji W Um; Hyeyoung Kim; Wongi Seol; Kwang C Chung
Journal:  Front Cell Neurosci       Date:  2017-05-11       Impact factor: 5.505

5.  Methylation of RCAN1.4 mediated by DNMT1 and DNMT3b enhances hepatic stellate cell activation and liver fibrogenesis through Calcineurin/NFAT3 signaling.

Authors:  Xue-Yin Pan; Hong-Mei You; Ling Wang; Yi-Hui Bi; Yang Yang; Hong-Wu Meng; Xiao-Ming Meng; Tao-Tao Ma; Cheng Huang; Jun Li
Journal:  Theranostics       Date:  2019-06-09       Impact factor: 11.556

6.  Covalent NEDD8 conjugation increases RCAN1 protein stability and potentiates its inhibitory action on calcineurin.

Authors:  Eun Hye Noh; Hee Sook Hwang; Hee Sun Hwang; Boram Min; Eunju Im; Kwang Chul Chung
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  PINK1 positively regulates IL-1β-mediated signaling through Tollip and IRAK1 modulation.

Authors:  Hyun Jung Lee; Kwang Chul Chung
Journal:  J Neuroinflammation       Date:  2012-12-17       Impact factor: 8.322

8.  The vertebrate RCAN gene family: novel insights into evolution, structure and regulation.

Authors:  Eva Serrano-Candelas; Domènec Farré; Álvaro Aranguren-Ibáñez; Sergio Martínez-Høyer; Mercè Pérez-Riba
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

9.  Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome.

Authors:  Karol Charkiewicz; Monika Zbucka-Kretowska; Joanna Goscik; Slawomir Wolczynski; Adam Lemancewicz; Piotr Laudanski
Journal:  J Immunol Res       Date:  2016-03-06       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.